Skip to main content

Advertisement

SpringerLink
Log in

Long Non-coding RNA CBR3 Antisense RNA 1 is Downregulated in Colorectal Cancer and Inhibits miR-29a-Mediated Cell Migration and Invasion

  • Original Paper
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

Although CBR3 Antisense RNA 1 (CBR3-AS1) has been characterized as an oncogenic long non-coding RNA (lncRNA) in several cancers, a recent study reported the downregulation of CBR3-AS1 in colorectal cancer (CRC). Therefore, we analyzed its role in CRC. CBR3-AS1 and microRNA-29a (miR-29a) expression in tissue samples from CRC patients were analyzed by RT-qPCR. The interaction between CBR3-AS1 and miR-29a was predicted by IntaRNA and validated by RNA pull-down assay. The location of CBR3-AS1 was analyzed by nuclear fractionation assay. CBR3-AS1 overexpression was performed to analyze its role in miR-29a expression. The roles of CBR3-AS1 and miR-29a in CRC cell migration and invasion were analyzed by Transwell assay. CBR3-AS1 was downregulated, and miR-29a was upregulated in CRC. CBR3-AS1 and miR-29a directly interacted with each other. CBR3-AS1 was localized in both nucleus and cytoplasm fractions. CBR3-AS1 overexpression failed to alter miR-29a expression but reduced its enhancing effects on cell invasion and migration. CBR3-AS1 is downregulated in CRC and inhibits miR-29a-mediated cell migration and invasion by sponging miR-29a.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. J. (2017). Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18010197

    Article  PubMed  PubMed Central  Google Scholar 

  2. Siegel, R. L., Miller, K. D., Goding Sauer, A., Fedewa, S. A., Butterly, L. F., Anderson, J. C., Cercek, A., Smith, R. A., & Jemal, A. (2020). Colorectal cancer statistics. CA: A Cancer Journal for Clinicians, 70(3), 145–164. https://doi.org/10.3322/caac.21601

    Article  Google Scholar 

  3. Araghi, M., Soerjomataram, I., Bardot, A., Ferlay, J., Cabasag, C. J., Morrison, D. S., De, P., Tervonen, H., Walsh, P. M., Bucher, O., Engholm, G., Jackson, C., McClure, C., Woods, R. R., Saint-Jacques, N., Morgan, E., Ransom, D., Thursfield, V., Møller, B., & Arnold, M. (2019). Changes in colorectal cancer incidence in seven high-income countries: A population-based study. The Lancet Gastroenterology & Hepatology, 4(7), 511–518. https://doi.org/10.1016/s2468-1253(19)30147-5

    Article  Google Scholar 

  4. Siegel, R. L., & Miller, K. D., & Jemal, A. (2019). Cancer statistics. CA: A Cancer Journal for Clinicians, 69(1), 7–34. https://doi.org/10.3322/caac.21551

    Article  Google Scholar 

  5. Acuna, S. A., Elmi, M., Shah, P. S., Coburn, N. G., & Quereshy, F. A. (2017). Preoperative localization of colorectal cancer: A systematic review and meta-analysis. Surgical Endoscopy, 31(6), 2366–2379. https://doi.org/10.1007/s00464-016-5236-8

    Article  PubMed  Google Scholar 

  6. Morse, M. A., Hochster, H., & Benson, A. (2020). Perspectives on treatment of metastatic colorectal cancer with immune checkpoint inhibitor therapy. The Oncologist, 25(1), 33–45. https://doi.org/10.1634/theoncologist.2019-0176

    Article  CAS  PubMed  Google Scholar 

  7. Loree, J. M., & Kopetz, S. (2017). Recent developments in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 9(8), 551–564. https://doi.org/10.1177/1758834017714997

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Lee, Y. T., Tan, Y. J., & Oon, C. E. (2018). Molecular targeted therapy: Treating cancer with specificity. European Journal of Pharmacology, 834, 188–196. https://doi.org/10.1016/j.ejphar.2018.07.034

    Article  CAS  PubMed  Google Scholar 

  9. Herzig, D. O., & Tsikitis, V. L. (2015). Molecular markers for colon diagnosis, prognosis and targeted therapy. Journal of Surgical Oncology, 111(1), 96–102. https://doi.org/10.1002/jso.23806

    Article  PubMed  Google Scholar 

  10. Manic, G., Signore, M., Sistigu, A., Russo, G., Corradi, F., Siteni, S., Musella, M., Vitale, S., De Angelis, M. L., Pallocca, M., Amoreo, C. A., Sperati, F., Di Franco, S., Barresi, S., Policicchio, E., De Luca, G., De Nicola, F., Mottolese, M., Zeuner, A., & De Maria, R. (2018). CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut, 67(5), 903–917. https://doi.org/10.1136/gutjnl-2016-312623

    Article  CAS  PubMed  Google Scholar 

  11. Khan, S. A., Zeng, Z., Shia, J., & Paty, P. B. (2017). EGFR gene amplification and KRAS mutation predict response to combination targeted therapy in metastatic colorectal cancer. Pathology Oncology Research: POR, 23(3), 673–677. https://doi.org/10.1007/s12253-016-0166-2

    Article  CAS  PubMed  Google Scholar 

  12. Zhang, Y., & Tang, L. (2018). The application of lncRNAs in cancer treatment and diagnosis. Recent Patents on Anti-cancer Drug Discovery, 13(3), 292–301. https://doi.org/10.2174/1574892813666180226121819

    Article  CAS  PubMed  Google Scholar 

  13. Xu, L., Zhu, H., Gao, F., Tang, Y., Zhu, Y., Sun, Z., & Wang, J. (2019). Upregulation of the long non-coding RNA CBR3-AS1 predicts tumor prognosis and contributes to breast cancer progression. Gene. https://doi.org/10.1016/j.gene.2019.100014

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hou, M., Wu, N., & Yao, L. (2021). LncRNA CBR3-AS1 potentiates Wnt/β-catenin signaling to regulate lung adenocarcinoma cells proliferation, migration and invasion. Cancer Cell International, 21(1), 36. https://doi.org/10.1186/s12935-020-01685-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Li, Q., Dai, Y., Wang, F., & Hou, S. (2016). Differentially expressed long non-coding RNAs and the prognostic potential in colorectal cancer. Neoplasma, 63(6), 977–983. https://doi.org/10.4149/neo_2016_617

    Article  CAS  PubMed  Google Scholar 

  16. Tang, W., Zhu, Y., Gao, J., Fu, J., Liu, C., Liu, Y., Song, C., Zhu, S., Leng, Y., Wang, G., Chen, W., Du, P., Huang, S., Zhou, X., Kang, J., & Cui, L. (2014). MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. British journal of cancer, 110(2), 450–458. https://doi.org/10.1038/bjc.2013.724

    Article  CAS  PubMed  Google Scholar 

  17. Mann, M., Wright, P. R., & Backofen, R. (2017). IntaRNA 2.0: Enhanced and customizable prediction of RNA-RNA interactions. Nucleic Acids Research, 45(W1), W435–W439. https://doi.org/10.1093/nar/gkx279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. He, P. Y., Yip, W. K., Chai, B. L., Chai, B. Y., Jabar, M. F., Dusa, N., Mohtarrudin, N., & Seow, H. F. (2017). Inhibition of cell migration and invasion by miR-29a-3p in a colorectal cancer cell line through suppression of CDC42BPA mRNA expression. Oncology Reports, 38(6), 3554–3566. https://doi.org/10.3892/or.2017.6037

    Article  CAS  PubMed  Google Scholar 

  19. Wang, J., Chen, X., Xie, C., Sun, M., Hu, C., Zhang, Z., Luan, L., Zhou, J., Zhou, J., Zhu, X., Ouyang, J., Dong, X., Li, D., Zhang, J., & Zhao, X. (2021). MicroRNA miR-29a inhibits colon cancer progression by downregulating B7–H3 expression: Potential molecular targets for colon cancer therapy. Molecular Biotechnology, 63(9), 849–861. https://doi.org/10.1007/s12033-021-00348-1

    Article  CAS  PubMed  Google Scholar 

  20. Zhang, Y., Meng, W., & Cui, H. (2018). LncRNA CBR3-AS1 predicts unfavorable prognosis and promotes tumorigenesis in osteosarcoma. Biomedicine & Pharmacotherapy, 102, 169–174. https://doi.org/10.1016/j.biopha.2018.02.081

    Article  CAS  Google Scholar 

  21. Romero-Cordoba, S. L., Salido-Guadarrama, I., Rodriguez-Dorantes, M., & Hidalgo-Miranda, A. (2014). miRNA biogenesis: Biological impact in the development of cancer. Cancer Biology & Therapy, 15(11), 1444–1455. https://doi.org/10.4161/15384047.2014.955442

    Article  CAS  Google Scholar 

Download references

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, EZhou Central Hospital, No. 9, Wenxing Road, Echeng District, Ezhou, 436000, Hubei, People’s Republic of China

    Mei Yang, Wenxi Chen, Haojie Liu, Liang Yu, Mingwu Tang & Yinghui Liu

Authors
  1. Mei Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenxi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haojie Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mingwu Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yinghui Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MY and WXC: manuscript writing, literature research and data analysis; HJL, LY: data analysis, experimental work and statistical analysis. MWT and YHL: literature research, project management and research design. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Wenxi Chen.

Ethics declarations

Conflict of interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical Approval

Ethical approval was obtained from the Ethics Committee of EZhou Central Hospital.

Informed Consent

All patients signed written informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

12033_2021_444_MOESM1_ESM.tif

Supplemental Figure 1 CBR3-AS1 increased the accumulation of CDC42BPA (A) and B7-H3 (B) mRNA in CRC cells. (*p<0.05) (TIF 6355 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, M., Chen, W., Liu, H. et al. Long Non-coding RNA CBR3 Antisense RNA 1 is Downregulated in Colorectal Cancer and Inhibits miR-29a-Mediated Cell Migration and Invasion. Mol Biotechnol 64, 773–779 (2022). https://doi.org/10.1007/s12033-021-00444-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12033-021-00444-2

Keywords

Search

Navigation